Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04312841 · OUTCOME

Overall Survival (OS)

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab · Source last updated 2025-02-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From trial enrollment to the occurrence of death due to any cause, assessed up to 2 years

What was measured

OS will be estimated with the method of KM, where KM curves will be drawn to aid with visualization and estimates provided with 95% confidence intervals.

Groups in this outcome

Treatment (Letermovir)

Beginning within 7 days of the first administration of standard alemtuzumab, patients receive letermovir PO (or IV over 1 hour if patient is unable to take PO for an extended period of time) daily on days 1-28. Cycles repeat every 28 days for up to 3 months after the last dose of alemtuzumab in the absence of unacceptable toxicity. Letermovir: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Letermovir)6

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Letermovir)8.3Not reported0.4NADue to low accrual the upper limit for the confidence interval was not able to be determined.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Due to low accrual the upper limit for the confidence interval was not able to be determined.
        group Id
        OG000
        lower Limit
        0.4
        upper Limit
        NA
        value
        8.3
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    units
    Participants
description
OS will be estimated with the method of KM, where KM curves will be drawn to aid with visualization and estimates provided with 95% confidence intervals.
dispersion Type
95% Confidence Interval
groups
  1. description
    Beginning within 7 days of the first administration of standard alemtuzumab, patients receive letermovir PO (or IV over 1 hour if patient is unable to take PO for an extended period of time) daily on days 1-28. Cycles repeat every 28 days for up to 3 months after the last dose of alemtuzumab in the absence of unacceptable toxicity. Letermovir: Given PO
    id
    OG000
    title
    Treatment (Letermovir)
param Type
MEDIAN
reporting Status
POSTED
time Frame
From trial enrollment to the occurrence of death due to any cause, assessed up to 2 years
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice